SG11202106394PA - Adaptation of enterovirus to vero cells and vaccine formulations thereof - Google Patents

Adaptation of enterovirus to vero cells and vaccine formulations thereof

Info

Publication number
SG11202106394PA
SG11202106394PA SG11202106394PA SG11202106394PA SG11202106394PA SG 11202106394P A SG11202106394P A SG 11202106394PA SG 11202106394P A SG11202106394P A SG 11202106394PA SG 11202106394P A SG11202106394P A SG 11202106394PA SG 11202106394P A SG11202106394P A SG 11202106394PA
Authority
SG
Singapore
Prior art keywords
enterovirus
adaptation
vero cells
vaccine formulations
vaccine
Prior art date
Application number
SG11202106394PA
Inventor
Amit Raychoudhuri
Krishna Murthy Ella
Original Assignee
Bharat Biotech Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bharat Biotech Int Ltd filed Critical Bharat Biotech Int Ltd
Publication of SG11202106394PA publication Critical patent/SG11202106394PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32311—Enterovirus
    • C12N2770/32321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32311—Enterovirus
    • C12N2770/32322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32311—Enterovirus
    • C12N2770/32334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32311—Enterovirus
    • C12N2770/32361—Methods of inactivation or attenuation
    • C12N2770/32363—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32311—Enterovirus
    • C12N2770/32371—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11202106394PA 2018-12-29 2019-12-27 Adaptation of enterovirus to vero cells and vaccine formulations thereof SG11202106394PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201841049814 2018-12-29
PCT/IN2019/050960 WO2020136683A1 (en) 2018-12-29 2019-12-27 Adaptation of enterovirus to vero cells and vaccine formulations thereof

Publications (1)

Publication Number Publication Date
SG11202106394PA true SG11202106394PA (en) 2021-07-29

Family

ID=71126945

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202106394PA SG11202106394PA (en) 2018-12-29 2019-12-27 Adaptation of enterovirus to vero cells and vaccine formulations thereof

Country Status (6)

Country Link
US (1) US20220160862A1 (en)
EP (1) EP3906051A4 (en)
CN (1) CN113329767A (en)
BR (1) BR112021012496A2 (en)
SG (1) SG11202106394PA (en)
WO (1) WO2020136683A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022070210A1 (en) * 2020-09-29 2022-04-07 Bharat Biotech International Limited Stable formulations of low abundance enteroviruses vaccines and process of manufacture thereof
CN114717201A (en) * 2021-04-17 2022-07-08 景均股份有限公司 Enterovirus D68 and enterovirus D68 vaccine suitable for vero cells and application thereof
CN118202248A (en) * 2021-09-10 2024-06-14 武田疫苗股份有限公司 Immunofocal assay for determining titres of dengue virus
CN114990075B (en) * 2022-04-20 2023-07-14 中国医学科学院医学生物学研究所 Coxsackie virus A group 10 vaccine strain applicable to human vaccine cell matrix culture and application thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103228293A (en) * 2010-11-30 2013-07-31 巴拉特生物技术国际有限公司 Vaccine formulation for prophylaxis and treatment of chandipura virus infections in mammals
AR102547A1 (en) 2014-11-07 2017-03-08 Takeda Vaccines Inc VACCINES AGAINST DISEASE OF HANDS, FEET AND MOUTH AND MANUFACTURING METHODS AND THEIR USE
US10752966B2 (en) * 2015-04-24 2020-08-25 Washington University Methods and compositions for detection of enterovirus D68
US9938588B2 (en) 2015-06-05 2018-04-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions and methods for detecting Enterovirus D68
CN107449915A (en) * 2017-07-17 2017-12-08 中国医学科学院医学生物学研究所 A kind of method for detecting serum moderate resistance EV D68 antiviral antibodies
SG11202007503WA (en) * 2018-02-07 2020-09-29 Bharat Biotech Int Ltd A process for enterovirus purification and inactivation and vaccine compositions obtained thereof
CN108424881B (en) * 2018-03-23 2021-07-27 中国食品药品检定研究院 Enterovirus type 68 and application thereof in preparation of EV-D68 infected animals

Also Published As

Publication number Publication date
EP3906051A1 (en) 2021-11-10
US20220160862A1 (en) 2022-05-26
WO2020136683A1 (en) 2020-07-02
BR112021012496A2 (en) 2021-11-30
EP3906051A4 (en) 2022-09-28
CN113329767A (en) 2021-08-31

Similar Documents

Publication Publication Date Title
SG11202106394PA (en) Adaptation of enterovirus to vero cells and vaccine formulations thereof
IL273979A (en) Methods of producing modified natural killer cells and methods of use
ZA201704985B (en) Oral care compositions and methods of use
EP3349783C0 (en) Compositions and methods relating to the treatment of diseases
HK1243942A1 (en) Sunitinib formulations and methods for use thereof in treatment of glaucoma
IL246352A0 (en) Compositions and methods of preparing airway cells
EP3458574A4 (en) Mesenchymal stem cell and use thereof for treatment of muscle injury and muscle-associated diseases
DK3372229T3 (en) PROCEDURES TO INCREASE TONIC INHIBITION AND TREATMENT OF ANGELMAN'S SYNDROME
PT3137635T (en) Rapid acting lactobacillus strains and their use to improve aerobic stability of silage
PL3154515T3 (en) Improvements to nasal compositions and method of use thereof
PT3551748T (en) Perinatal tissue derived mesenchymal stem cells: method of preparation and uses thereof
IL285928A (en) Fulvestrant formulations and methods of their use
HK1252343A1 (en) Compositions and methods for the treatment of viral infection
GB201404403D0 (en) Compositions and methods relating to the treatment of diseases
DK3722291T3 (en) INDOLINONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF FIBROTIC DISEASES
HK1255379A1 (en) Hepatitis c virus immunogenic compositions and methods of use thereof
IL274433A (en) Fulvestrant formulations and methods of their use
GB2568562B (en) Moldable compositions and methods of using thereof
IL283136A (en) Antibodies to mucin-16 and methods of use thereof
SG11202103907PA (en) Formulations of anti-rsv antibodies and methods of use thereof
IL269308A (en) Methods of treatment of hla-b27 related inflammatory diseases and compositions related to same
DK3194602T3 (en) RELATIONSHIPS AND PROCEDURES TO ENHANCE VIRUS REVERSION TO HUMAN HEMATOPOIETIC CELLS
EP3420076C0 (en) Methods of producing and characterizing virus vaccine and virus vaccine composition
ZA202006280B (en) Live-attenuated yellow fever virus strain adapted to grow on vero cells and vaccine composition comprising the same
IL274563A (en) Methods of using and compositions containing dulaglutide